B. Riley Estimates LifeMD's Q1 Earnings (NASDAQ:LFMD)

LifeMD, Inc. (NASDAQ:LFMD - Free Report) - Research analysts at B. Riley issued their Q1 2025 EPS estimates for shares of LifeMD in a note issued to investors on Tuesday, March 11th. B. Riley analyst A. Schock anticipates that the company will earn ($0.07) per share for the quarter. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for LifeMD's current full-year earnings is ($0.56) per share. B. Riley also issued estimates for LifeMD's Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at $0.03 EPS and FY2025 earnings at ($0.10) EPS.

Several other research firms have also recently commented on LFMD. Lake Street Capital began coverage on shares of LifeMD in a research report on Tuesday, December 10th. They issued a "buy" rating and a $12.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $15.00 target price on shares of LifeMD in a research report on Tuesday, March 11th. KeyCorp dropped their target price on shares of LifeMD from $10.00 to $7.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Mizuho assumed coverage on shares of LifeMD in a research report on Wednesday, December 4th. They issued a "neutral" rating and a $7.00 target price for the company. Finally, HC Wainwright increased their price target on shares of LifeMD from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $11.43.

Remove Ads

LifeMD Stock Down 1.1 %

Shares of NASDAQ:LFMD traded down $0.06 on Friday, hitting $5.65. The company had a trading volume of 875,740 shares, compared to its average volume of 804,835. The firm's 50-day simple moving average is $5.68 and its two-hundred day simple moving average is $5.39. LifeMD has a 1 year low of $3.99 and a 1 year high of $12.88. The firm has a market capitalization of $251.90 million, a price-to-earnings ratio of -8.83 and a beta of 1.50.

LifeMD (NASDAQ:LFMD - Get Free Report) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.02. The firm had revenue of $64.26 million for the quarter, compared to analysts' expectations of $57.43 million.

Insider Buying and Selling at LifeMD

In other LifeMD news, CEO Justin Schreiber sold 50,000 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $7.55, for a total transaction of $377,500.00. Following the completion of the sale, the chief executive officer now directly owns 2,653,715 shares in the company, valued at approximately $20,035,548.25. This trade represents a 1.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Jessica Friedeman sold 30,000 shares of the firm's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $5.66, for a total transaction of $169,800.00. Following the sale, the chief marketing officer now owns 170,000 shares of the company's stock, valued at approximately $962,200. This represents a 15.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 105,000 shares of company stock worth $677,050. 15.97% of the stock is owned by corporate insiders.

Institutional Trading of LifeMD

A number of institutional investors and hedge funds have recently bought and sold shares of LFMD. Marshall Wace LLP boosted its holdings in shares of LifeMD by 522.9% during the 4th quarter. Marshall Wace LLP now owns 371,473 shares of the company's stock valued at $1,839,000 after acquiring an additional 311,841 shares during the last quarter. Royce & Associates LP boosted its holdings in shares of LifeMD by 23.9% during the 4th quarter. Royce & Associates LP now owns 1,115,991 shares of the company's stock valued at $5,524,000 after acquiring an additional 214,950 shares during the last quarter. State Street Corp boosted its holdings in shares of LifeMD by 20.0% during the 3rd quarter. State Street Corp now owns 1,155,495 shares of the company's stock valued at $6,055,000 after acquiring an additional 192,861 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of LifeMD by 21.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,294 shares of the company's stock valued at $4,610,000 after acquiring an additional 165,378 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of LifeMD by 45.2% during the 4th quarter. Renaissance Technologies LLC now owns 510,000 shares of the company's stock valued at $2,524,000 after acquiring an additional 158,796 shares during the last quarter. 35.52% of the stock is currently owned by institutional investors.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.